Core Viewpoint - Nanmo Bio experienced a slight decline in stock price, with significant financing activity indicating a high level of market interest and liquidity [1][2]. Group 1: Financial Performance - For the period from January to September 2025, Nanmo Bio achieved a revenue of 303 million yuan, representing a year-on-year growth of 14.29% [2]. - The net profit attributable to shareholders for the same period was 26.76 million yuan, showing a substantial year-on-year increase of 276.14% [2]. Group 2: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for Nanmo Bio reached 6,687, an increase of 2.53% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 2.47% to 11,658 shares [2]. - The company has distributed a total of 30.04 million yuan in dividends since its A-share listing, with 10.00 million yuan distributed over the past three years [3]. Group 3: Financing and Margin Data - On November 6, 2023, Nanmo Bio recorded a financing buy-in of 2.72 million yuan, while the financing repayment amounted to 4.31 million yuan, resulting in a net financing outflow of 1.59 million yuan [1]. - The total margin balance for Nanmo Bio as of November 6, 2023, was 73.85 million yuan, accounting for 2.10% of its market capitalization, which is above the 70th percentile of the past year [1]. - There were no short sales or borrowings on November 6, 2023, indicating a lack of bearish sentiment in the market [1].

Group 1 - The core point of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant breakthrough in gene editing technology [1] - The trials are approved by the FDA and aim to systematically evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - There have been multiple advancements in gene editing technology globally, including successful transplants of gene-edited organs and new treatment approaches for genetic disorders [1] Group 2 - Huazhong Securities notes that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production and reducing drug production costs [2] - A total of 22 listed companies in the A-share market have gene editing technology reserves, with several companies reporting profitability in their third-quarter results [3] - Notable companies include Shuanglu Pharmaceutical, which reported a net profit of 141 million yuan, and Mengcao Ecological, which saw a 48.73% year-on-year increase in net profit [3][4] Group 3 - Companies like Wanjian Medical are collaborating with research institutions to develop cotton varieties using gene editing technology, indicating the application of gene editing beyond human health [5] - The number of institutional ratings for gene editing concept stocks shows significant interest, with companies like Wanjian Medical and Huaxi Biological receiving the highest number of ratings [6]

证券代码：688265 证券简称：南模生物 公告编号：2025-068 上海南方模式生物科技股份有限公司 关于回购股份集中竞价减持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 回购股份的基本情况 上海南方模式生物科技股份有限公司（以下简称"公司"）于 2024 年 2 月 23 日至 2024 年 5 月 22 日期间通过集中竞价交易方式累计回购股份 788,912 股，占 公司总股本的 1.0119%。前述回购的股份拟用于维护公司价值及股东权益，将在 披露回购实施结果公告（即 2024 年 5 月 23 日）12 个月后采用集中竞价的方式 出售，并在披露股份回购实施结果公告日后 3 年内完成转让；若公司未能在上述 期限内完成转让，尚未转让的已回购股份将予以注销。 减持计划的进展情况 2025 年 8 月 29 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《关于回购股份集中竞价减持股份计划公告》（公告编号：2025-054），公司计划 按照市场价格，通过集 ...

证券代码：688265 证券简称：南模生物 公告编号：2025-069 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 6 日（星期四）至 11 月 12 日（星期三） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 上海南方模式生物科技股份有限公司（以下简称"公司"）邮箱 ir@modelorg.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 公司已于 2025 年 10 月 30 日发布公司《2025 年第三季度报告》， 为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、 财务状况，公司计划于 2025 年 11 月 13 日（星期四）15:00-16:30 参 加 2025 年上海辖区上市公司三季报集体业绩说明会，就投资者关心 的问题进行交流。 会议召开时间：2025 年 11 月 13 日（星期四）15:00-16:30 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow. ...

Core Points - Nanmo Biology's stock price fell by 3.72% to 48.72 yuan on November 3 [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 28, 2021, with an initial offering price of 84.62 yuan per share [1] - The stock is currently in a state of decline, having reached a peak price of 82.00 yuan on its first trading day [1] Fundraising and Financials - Nanmo Biology raised a total of 1.649 billion yuan through its initial public offering (IPO), with a net amount of 1.468 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 1.068 billion yuan [1] - The company planned to use the funds for various projects, including a biological research base, a genetically modified model resource library, and working capital [1] Issuance Costs - The total issuance costs for the IPO amounted to 181 million yuan, with underwriting fees accounting for 158 million yuan [1]

Core Insights - The medical services sector experienced a rise of 1.67% on October 31, with Haitai Biological leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Services Sector Performance - Haitai Biological (300683) closed at 34.46, up 11.20% with a trading volume of 158,200 shares and a transaction value of 530 million [1] - Other notable performers included: - Nanmo Biological (688265) at 50.60, up 9.98% [1] - Nuo Si Ge (301333) at 68.59, up 7.00% [1] - Yangguang Nuohe (688621) at 58.75, up 5.10% [1] - *ST Biological (000504) at 9.57, up 5.05% [1] Capital Flow Analysis - The medical services sector saw a net inflow of 461 million from institutional investors, while retail investors experienced a net inflow of 918,230 [2] - Notable capital flows included: - Innovation Medical (002173) with a net inflow of 14.416 million from institutional investors [3] - Tai Ge Medical (300347) with a net inflow of 70.6534 million from institutional investors [3] - Zhaoyan New Drug (603127) with a net inflow of 53.6731 million from institutional investors [3]

Group 1 - The core viewpoint of the news is that Nanmo Biological has seen a stock price increase of 5.09%, reaching 48.35 yuan per share, with a total market capitalization of 3.77 billion yuan [1] - Nanmo Biological, established on September 20, 2000, specializes in the research, production, and sales of genetically modified animal models, with its main business revenue composition being: standardized models 48.34%, model technical services 21.92%, model breeding 19.50%, customized models 9.34%, and others 0.91% [1] Group 2 - Tianhong Fund's Tianhong Medical Health A (001558) has entered the top ten circulating shareholders of Nanmo Biological, holding 377,400 shares, which is 0.48% of the circulating shares, with an estimated floating profit of approximately 883,200 yuan [2] - Tianhong Medical Health A was established on June 30, 2015, with a latest scale of 263 million yuan, and has achieved a year-to-date return of 36.83% [2] Group 3 - The fund manager of Tianhong Medical Health A is Lü Qiao, who has a total fund asset scale of 506 million yuan, with the best fund return during the tenure being 41.15% and the worst being 40.68% [3]

Core Viewpoint - Nanmo Bio is a leading supplier of genetically modified animal models in China, providing critical technical support for the biopharmaceutical industry with a full industry chain service capability [1] Group 1: Business Performance - In Q3 2025, Nanmo Bio achieved a revenue of 303 million yuan, ranking 24th among 29 companies in the industry [2] - The company's net profit for the same period was 26.76 million yuan, placing it 19th in the industry [2] - Revenue breakdown: standardized models accounted for 48.34% (94.62 million yuan), model technical services for 21.92% (42.90 million yuan), model breeding for 19.50% (38.17 million yuan), customized models for 9.34% (18.29 million yuan), and other revenue for 0.91% (1.77 million yuan) [2] Group 2: Financial Ratios - As of Q3 2025, Nanmo Bio's debt-to-asset ratio was 10.38%, down from 11.82% year-on-year and significantly lower than the industry average of 22.79%, indicating strong solvency [3] - The company's gross profit margin was 52.87%, an increase from 43.63% year-on-year and above the industry average of 37.70%, reflecting strong profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 2.53% to 6,687, while the average number of circulating A-shares held per shareholder decreased by 2.47% to 11,700 [5] - Tianhong Medical Health A became a new major shareholder with 377,400 shares, while Rongtong Health Industry Flexible Allocation Mixed A/B exited the top ten circulating shareholders [5] Group 4: Executive Compensation - The chairman, Fei Jian, received a salary of 500,000 yuan in 2024, an increase of 100,000 yuan from 2023 [4] - The company is controlled by Shanghai Dish Enterprises Management Consulting Co., Ltd., with Wang Mingjun and Fei Jian as the actual controllers [4]

Core Insights - Nanmo Biological (688265.SH) reported a total operating revenue of 303 million yuan for Q3 2025, ranking 35th among disclosed peers [1] - The company's net profit attributable to shareholders was 26.76 million yuan, ranking 25th among disclosed peers [1] - Operating cash flow was 19.64 million yuan, ranking 29th among disclosed peers [1] Financial Metrics - The latest debt-to-asset ratio is 10.38% [3] - The latest gross profit margin is 52.87% [3] - The latest return on equity (ROE) is 1.57%, ranking 25th among disclosed peers [3] - The diluted earnings per share (EPS) is 0.34 yuan [3] - The total asset turnover ratio is 0.16 times, ranking 35th among disclosed peers [3] - The inventory turnover ratio is 9.37 times [3] Shareholder Information - The number of shareholders is 6,687, with the top ten shareholders holding 58.58 million shares, accounting for 75.13% of the total share capital [3] - The top ten shareholders and their holdings are as follows: - Shanghai Dish Stone Enterprise Management Consulting Co., Ltd.: 35.6% - Shanghai Science and Technology Venture Capital Co., Ltd.: 13.81% - Suzhou Haiwang Hezhong No.1 Equity Investment Partnership (Limited Partnership): 11.1% - Shanghai Pudong New Industry Investment Co., Ltd.: 7.86% - Kangjun Investment Management (Beijing) Co., Ltd.: 2.00% - Zhang Kui: 2.00% - Qu Fabing: 1.01% - Shanghai Huashen Asset Management Co., Ltd.: 0.64% - Shanghai Puyu Enterprise Management Consulting Partnership (Limited Partnership): 0.58% - China Merchants Securities Co., Ltd.: 0.48% [3]

Core Insights - The company Nanmo Biology (688265.SH) reported a total revenue of 303 million yuan for the first three quarters of 2025, representing a year-on-year growth of 14.29% [1] - The net profit attributable to shareholders was 26.76 million yuan, a significant improvement from a loss of 15.19 million yuan in the same period last year [1] - The basic earnings per share stood at 0.34 yuan [1]